We hypothesize that the risk for drug-drug interactions and associated ADRs are greater in the setting of genetically compromised metabolizing enzyme function. The goal of this study is to develop tools to assess the impact of genetic variants on CYP450 metabolic capacity using a novel, high-throughput platform. Additionally, we will investigate the impact of genetic variants in the context of drug-drug interactions. The pharmacogenomic knowledge gained from our investigations will create a database useful for predicting drug-gene and drug-gene-drug interactions that will enable more individualized drug treatment plans.
|Effective start/end date||2/1/15 → 1/31/17|
- Pharmaceutical Research and Manufacturers of America Foundation, Inc. (Award Letter 2/5/15)